Tumors of the Major Salivary Glands
Tumors of the Major Salivary Glands
复制标题
主要唾液腺肿瘤
DOI：
10.5631/jibirin.74.5special_1044
复制
发表时间：
1981
期刊：
影响因子：
--
通讯作者：
S. Nozaki
中科院分区：
文献类型：
--
作者：
S. Nozaki
本文根据世界卫生组织（WHO）对108例大涎腺肿瘤及其相关疾病的分类，对大涎腺肿瘤的临床表现、诊断技术、结果显示，腮腺是最常见的涎腺肿瘤，多形性腺瘤是最常见的肿瘤。腮腺肿瘤81例，良恶性肿瘤之比为2.37：1。其余均为颌下腺及舌下腺肿瘤，良恶性比为1.71：1。除6例腮腺良性肿瘤行浅叶或全叶切除外，其余均行肿瘤摘除术。腮腺恶性肿瘤行肿瘤摘除术9例，浅叶切除术2例，全叶切除术10例。21例中4例加用放疗，11例加用放化疗。对所有的下颌下腺或舌下腺肿瘤均行肿瘤腺体全切除术，并对17例随访1年以上的腮腺恶性肿瘤按美国癌症分期和最终结果报告联合委员会（1975）的建议进行分期。T1N0M0、T2N0M0、T3N0M0、T3N1M0和T3N1M1的5年生存率分别为100%、75%、0%、0%和0%。
One-hundred and eight cases of major salivary gland tumors and allied conditions treated in the Department of Otolaryngology, Mie University Hospital were reviewed according to the classification of the World Health Organization (WHO) and analyzed in terms of mode of presentation, diagnostic technique, treatment and end results.It was shown that the commonly involved salivary gland was the parotid gland and the most prevalent tumor was pleomorphic adenoma. Of the 108 cases, 81 were parotid tumor cases, and the ratio of benign to malignant tumors was 2.37:1. The remaining cases were tumors of submandibular and sublingual gland origin, and the ratio of benign to malignant was 1.71:1.We have principally performed enucleation surgery for all the benign parotid tumors, except six cases in which either superficial lobectomy or total lobectomy was performed. For malignant parotid tumors, enucleation surgery was performed in 9 cases, superficial lobectomy in two cases and total lobectomy in 10 cases. Of the above 21 cases, irradiation was added in 4 cases, combination therapy of irradiation and chemotherapy was administered in 11 cases. For all the cases of the tumor of the submandibular gland or sublingual gland, total extirpation of the gland with the tumor was performed.In accordance with the proposal of the American Joint Committee for Cancer Staging and End Results Reporting (1975), staging of 17 cases with malignant parotid tumors, which were followed more than one year, was determined. The five-year survival rate according to the stage was found to be 100% for T1N0M0, 75% for T2N0M0, 0% for T3N0M0, 0% for T3N1M0 and 0% for T3N1M1.The literature on new diagnostic procedures, treatment and prognosis was reviewed.